CSIMarket
 
Prime Medicine Inc   (PRME)
Other Ticker:  
 
 
Price: $7.0000 $0.34 5.105%
Day's High: $7.06 Week Perf: -4.63 %
Day's Low: $ 6.71 30 Day Perf: -25.45 %
Volume (M): 642 52 Wk High: $ 17.20
Volume (M$): $ 4,492 52 Wk Avg: $10.60
Open: $6.83 52 Wk Low: $5.54



 Market Capitalization (Millions $) 636
 Shares Outstanding (Millions) 91
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) -146
 Capital Exp. (TTM) (Millions $) 9

Prime Medicine Inc
Prime Medicine Inc is a biotechnology company that specializes in developing gene editing therapies to treat genetic diseases. Their mission is to provide innovative solutions using CRISPR technology to correct disease-causing genetic mutations. Prime Medicine Inc aims to revolutionize the field of gene therapy by developing safe and effective treatments for a wide range of genetic disorders, with a particular focus on diseases with limited treatment options. They are committed to advancing the field of precision medicine and improving the quality of life for patients affected by genetic diseases.


   Company Address: 21 Erie Street Cambridge 2139 MA
   Company Phone Number: 564-0013   Stock Exchange / Ticker: NASDAQ PRME
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Financing Agreement

Prime Medicine Closes Upsized Public Offering, Raises $161 Million

Published Tue, Feb 20 2024 9:01 PM UTC


Cambridge-based biotechnology company, Prime Medicine, Inc. (Nasdaq: PRME), has successfully completed its underwritten upsized public offering, generating significant funds amounting to approximately $161.0 million. The offering comprised of 22,560,001 shares of Prime Medicine's common stock, including the underwriters' full exercise of their option to purchase an addi...

Management Announcement

Prime Medicine Announces Upsized Public Offering as it Pursues Groundbreaking Genetic Therapies

Published Thu, Feb 15 2024 4:51 AM UTC



In a groundbreaking move, Prime Medicine, Inc. (Nasdaq: PRME), a leading biotechnology company dedicated to revolutionizing the field of genetic therapies, has announced the pricing of an underwritten upsized public offering. This strategic move underscores Prime Medicine's commitment to delivering a new class of differentiated one-time curative genetic therapies.<...

Shares

Prime Medicine Initiates Public Offering of Common Stock, Boosting Shareholder Confidence

Published Wed, Feb 14 2024 9:05 PM UTC



In an exciting development for the biotechnology industry, Prime Medicine, Inc. has announced the commencement of an underwritten public offering of $125.0 million worth of shares of its common stock. As a pioneering company dedicated to offering innovative one-time curative genetic therapies, Prime Medicine's decision to initiate the offering signifies a promising...

Financing Agreement

Prime Medicine Secures $15 Million to Revolutionize Cystic Fibrosis Treatment

Published Thu, Jan 25 2024 1:00 PM UTC

Prime Medicine Receives $15 Million from Cystic Fibrosis Foundation to Accelerate Genetic Therapies for Cystic Fibrosis
CAMBRIDGE, Mass., Jan. 25, 2024 - Prime Medicine, Inc., a pioneering biotechnology company specializing in groundbreaking one-time curative genetic therapies, announced today that it has secured a funding agreement worth up to $15 million from the Cysti...

Prime Medicine Inc

Strong Performance in Earnings Boosted by $0.20 Million Tax Provisions for Prime Medicine Inc.2.

Biotechnology & Pharmaceuticals sector advisors have been closely analyzing the first quarter of 2023 earnings, and today they reported an operating deficit of $-40.033 million from Prime Medicine Inc. Despite the lack of any revenue reported for the January to March 31 2023 reporting period, the entity had a constructive reporting period.
Investors may be wondering how to measure if this was a positive reporting period. One key indicator is that earnings increased from $0.000 million in the previous year to $0.202 million in the most recent fiscal period. This is a positive sign for the company's future.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com